Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.